Reade CJ[au] - Search Results

Year	Number of Results
2008	1
2012	1
2013	5
2014	4
2015	4
2018	1
2019	1
2020	1
2021	3
2022	3
2023	0

1

Current Quality of Gynecologic Cancer Care in North America.

Reade CJ, Elit LM. Reade CJ, et al. Obstet Gynecol Clin North Am. 2019 Mar;46(1):1-17. doi: 10.1016/j.ogc.2018.09.001. Obstet Gynecol Clin North Am. 2019. PMID: 30683257 Review.

2

Recommendations for Follow-up Care for Gynecologic Cancer Survivors.

Elit L, Reade CJ. Elit L, et al. Among authors: reade cj. Obstet Gynecol. 2015 Dec;126(6):1207-1214. doi: 10.1097/AOG.0000000000001129. Obstet Gynecol. 2015. PMID: 26551194 Review.

3

Surgery for early stage cervical cancer: how radical should it be?

Reade CJ, Eiriksson LR, Covens A. Reade CJ, et al. Gynecol Oncol. 2013 Oct;131(1):222-30. doi: 10.1016/j.ygyno.2013.07.078. Epub 2013 Jul 14. Gynecol Oncol. 2013. PMID: 23863357 Review.

4

Sentinel lymph node biopsy in vulvar cancer: Systematic review, meta-analysis and guideline recommendations.

Covens A, Vella ET, Kennedy EB, Reade CJ, Jimenez W, Le T. Covens A, et al. Among authors: reade cj. Gynecol Oncol. 2015 May;137(2):351-61. doi: 10.1016/j.ygyno.2015.02.014. Epub 2015 Feb 20. Gynecol Oncol. 2015. PMID: 25703673 Review.

5

Gender imbalance in gynecologic oncology authorship and impact of COVID-19 pandemic.

Mah SJ, Makkar M, Huang K, Anpalagan T, Reade CJ, Nguyen JMV. Mah SJ, et al. Among authors: reade cj. Int J Gynecol Cancer. 2022 May 3;32(5):583-589. doi: 10.1136/ijgc-2021-003296. Int J Gynecol Cancer. 2022. PMID: 35304410 Free PMC article.

6

Systemic therapy in squamous cell carcinoma of the vulva: current status and future directions.

Reade CJ, Eiriksson LR, Mackay H. Reade CJ, et al. Gynecol Oncol. 2014 Mar;132(3):780-9. doi: 10.1016/j.ygyno.2013.11.025. Epub 2013 Dec 1. Gynecol Oncol. 2014. PMID: 24296343 Review.

7

Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis.

Reade CJ, Riva JJ, Busse JW, Goldsmith CH, Elit L. Reade CJ, et al. Gynecol Oncol. 2013 Sep;130(3):674-81. doi: 10.1016/j.ygyno.2013.06.029. Epub 2013 Jun 30. Gynecol Oncol. 2013. PMID: 23822892 Review.

8

The five-factor modified frailty index predicts adverse postoperative and chemotherapy outcomes in gynecologic oncology.

Mah SJ, Anpalagan T, Marcucci M, Eiriksson L, Reade CJ, Jimenez W, Carlson V, Nguyen JMV. Mah SJ, et al. Among authors: reade cj. Gynecol Oncol. 2022 Jul;166(1):154-161. doi: 10.1016/j.ygyno.2022.05.012. Epub 2022 May 20. Gynecol Oncol. 2022. PMID: 35606168

9

The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.

Reade CJ, McVey RM, Tone AA, Finlayson SJ, McAlpine JN, Fung-Kee-Fung M, Ferguson SE. Reade CJ, et al. J Obstet Gynaecol Can. 2014 Feb;36(2):133-140. doi: 10.1016/S1701-2163(15)30659-9. J Obstet Gynaecol Can. 2014. PMID: 24518912 Review.

10

Trends in quality indicators of end-of-life care for women with gynecologic malignancies in Ontario, Canada.

Mah SJ, Seow H, Schnarr K, Reade CJ, Gayowsky A, Chan KKW, Sinnarajah A. Mah SJ, et al. Among authors: reade cj. Gynecol Oncol. 2022 Sep 23:S0090-8258(22)01822-4. doi: 10.1016/j.ygyno.2022.09.008. Online ahead of print. Gynecol Oncol. 2022. PMID: 36163056

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results